AstraZeneca secured global rights to Dizal Pharmaceutical’s oral EGFR exon 20 insertion therapy Zegfrovy (sunvozertinib) in a licensing agreement valued at up to $1.5 billion. The structure includes a $600 million upfront payment and additional development and sales milestones. Zegfrovy is positioned for adult patients with locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations after prior platinum chemotherapy, where it has approval in both the US and China. Dizal’s WU-Kong28 Phase III results, published in The New England Journal of Medicine, reported superior progression-free survival versus platinum-doublet chemotherapy in the first-line setting. For biotech and pharma planning, the deal consolidates AstraZeneca’s targeted oncology roadmap and provides a template for monetizing China-originated development through global commercialization rights.